TransCode Therapeutics Inc (NASDAQ:RNAZ) does about 2.08M shares in volume on a normal day but saw 2569635 shares change hands in the recent trading day. The company now has a market cap of 12.09M USD. Its current market price is $0.70, marking a decrease of -4.03% compared to the previous close of $0.73. The 52 week high reached by this stock is $21.20 whilst the lowest price level in 52 weeks is $0.22.
TransCode Therapeutics Inc (RNAZ) has a 20-day trading average at $0.5005 and the current price is -96.70% off the 52-week high compared with 224.07% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.3575 and its 200-day simple moving average is $1.0340. If we look at the stock’s price movements over the week, volatility stands at 25.26%, which increases to 27.52% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 64.34 to suggest the stock is neutral.
The consensus objective for the share price is $3.00, suggesting that the stock has a potential upside of 76.67% over the period.
The current price level is 39.87%, 95.83%, and -32.30% away from its SMA20, SMA50, and SMA200 respectively, with the RNAZ price moving below the 50-day SMA on current market day. TransCode Therapeutics Inc (RNAZ) stock is up 18.78% over the week and 176.68% over the past month. Its price is -89.38% year-to-date and -96.20% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -67.2 below consensus estimates by -7.2. The company’s next earnings report forecasts estimating quarterly EPS at -0.49 and -2.06 for whole year. Expected sales for next quarter are $300k, which analysts say will come at $500k for the current fiscal year and next year at $1M. In addition, estimates put the company’s current quarterly revenue at an average of $300k.
To reach the target analysts have set, the stock logically needs to grow 76.67 percent from here.
The company has a return on investment of -1354.12% and return on equity of -1048.70%. The beta has a value of 0.61. Price to book ratio is 3.85.
